Genentech/IDEC collaborating on B-cell lymphoma, leukemia with IDEC's anti-CD20 monoclonal antibody.
Executive Summary
GENENTECH/IDEC ANTI-CD20 MAb FOR B-CELL LYMPHOMA 39424COLLABORATION expects to have IDEC's anti-CD 20 monoclonal antibody, IDEC-C2B8, in Phase III clinical trials by mid-1995 for non-Hodgkin's B-cell lymphomas (NHL), the companies said jointly March 16. Genentech and IDEC are planning additional studies for the primary indication, as well as for other B-cell cancers, such as intermediate-grade NHL and chronic lymphocytic leukemia, Genentech said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth